1954 studies found for:    melanoma
Show Display Options
Rank Status Study
21 Unknown  Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Drug: cyclophosphamide
22 Completed
Has Results
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: IFA (incomplete Freund's adjuvant);   Biological: p946;   Biological: p946/tet-p;   Biological: Tet-p
23 Active, not recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Pharmacological Study;   Biological: Recombinant Flt3 Ligand
24 Recruiting Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Conditions: Melanoma;   Oligometastatic Melanoma
Interventions: Drug: Nivolumab 1mg/kg;   Drug: Ipilimumab;   Drug: Nivolumab 3 mg/kg
25 Completed
Has Results
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine;   Biological: tyrosinase peptide
26 Terminated Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: medical chart review
27 Recruiting Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Condition: Metastatic Melanoma to the Groin Lymph Nodes
Interventions: Procedure: Inguinal Lymphadenectomy;   Procedure: Ilio-inguinal Lymphadenectomy
28 Active, not recruiting A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Condition: High Risk Melanoma
Interventions: Drug: Ipilumimab;   Radiation: Radiation
29 Unknown  A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma
Conditions: Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Intervention: Biological: CB-10-01 (Transgenic Lymphocyte Immunization)
30 Completed Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Condition: Melanoma
Intervention: Other: Sampling of blood
31 Unknown  Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
32 Completed Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
33 Completed Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
34 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
35 Recruiting Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
Conditions: Melanoma;   Brain Metastases
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
36 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Condition: Malignant Melanoma
Interventions: Biological: A2/4-1BBL melanoma vaccine;   Procedure: DNP sensititzation;   Drug: Cyclophosphamide
37 Completed Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Condition: Melanoma
Interventions: Biological: Autologous, DNP-modified vaccine (M-Vax);   Biological: Autologous, DNP-Modified Melanoma Vaccine;   Biological: Autologous, DNP-Modified Vaccine
38 Completed Vaccine Therapy in Treating Patients With Advanced Melanoma
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Procedure: biopsy
39 Terminated Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
Condition: Melanoma
Intervention: Biological: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
40 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years